Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 35%
Buy 20%
Hold 40%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is a well-established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its multiple sclerosis franchise, historically one of its key revenue generators, is facing competition, but is supported by collaborations with partners Roche and Eisai. Additionally, Biogen's newer franchises, including Spinraza, Leqembi, Skyclarys, Zurzuvae, and Qalsody, have promising data and strong potential in their respective indications. The company also has a strong pipeline with potential successes in rare kidney indications, CNS diseases, and oncology. Overall, the company's strong portfolio, promising pipeline, and clear focus on sustainability contribute to a positive outlook for Biogen's stock.

Bears say

Biogen is heavily reliant on its multiple sclerosis franchise, which faces competition and potential loss of exclusivity from biosimilars in the coming years. Its newer franchises have potential, but have faced challenges in clinical trials and there may be risks associated with their commercial success. Biogen's recent strategic initiatives may have a positive impact, but there are still uncertainties surrounding pipeline and business development. Overall, the company's outlook is negative due to these factors and the potential for decreased cash flows in the future.

Biogen (BIIB) has been analyzed by 20 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 20 analysts, Biogen (BIIB) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $210.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $210.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.